These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36198840)

  • 1. Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients.
    Wang N; Evans J; Sawant S; Sindone J; Lal S
    Heart Fail Rev; 2023 Jul; 28(4):949-959. PubMed ID: 36198840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Guideline-Directed Medical Therapy in Heart Failure Patients With and Without Chronic Kidney Disease: A Meta-Analysis of 63,677 Patients.
    Clark KM; Mahboob F; Evans J; Sun JH; Wang N
    Heart Lung Circ; 2024 Mar; 33(3):281-291. PubMed ID: 38365495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
    Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.
    Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH
    J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.
    Danielson C; Lileikyte G; Ouwerkerk W; S P Lam C; Erlinge D; Teng TK
    ESC Heart Fail; 2022 Aug; 9(4):2753-2761. PubMed ID: 35603531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
    Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
    Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients.
    Srivastava PK; DeVore AD; Hellkamp AS; Thomas L; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; Hernandez AF; Fonarow GC
    JACC Heart Fail; 2021 Jan; 9(1):28-38. PubMed ID: 33309579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
    Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
    JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
    Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF).
    Patil T; Ali S; Kaur A; Akridge M; Eppes D; Paarlberg J; Parashar A; Jarmukli N
    J Cardiovasc Transl Res; 2022 Dec; 15(6):1424-1435. PubMed ID: 35501544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
    Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
    ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
    Sumarsono A; Xie L; Keshvani N; Zhang C; Patel L; Alonso WW; Thibodeau JT; Fonarow GC; Van Spall HGC; Messiah SE; Pandey A
    Circulation; 2024 Feb; 149(7):510-520. PubMed ID: 38258605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U; Ergin I; Kıvrak T; Yılmaz Öztekin GM; Tanık VO; Özdemir İ; Avcı Demir F; Doğduş M; Şen T; Altınsoy M; Üstündağ S; Urgun ÖD; Sinan ÜY; Uygur B; Yeni M; Özçalık E
    ESC Heart Fail; 2023 Dec; 10(6):3677-3689. PubMed ID: 37804042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction.
    Batchelor RJ; Nan Tie E; Romero L; Hopper I; Kaye DM
    Am J Cardiol; 2023 Feb; 188():52-60. PubMed ID: 36473305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
    Bryan Richard S; Huang B; Liu G; Yang Y; Luo S
    Clin Cardiol; 2021 Apr; 44(4):463-471. PubMed ID: 33638556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction.
    De Marzo V; Savarese G; Tricarico L; Hassan S; Iacoviello M; Porto I; Ameri P
    J Intern Med; 2022 Aug; 292(2):333-349. PubMed ID: 35332595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.